Medical Subject Headings (MeSH): Molecular Targeted Therapy

Molecular targeted therapy is a type of treatment that uses drugs or other substances to block specific molecules or pathways involved in the growth and spread of cancer cells. This approach is based on the fact that cancer cells often have genetic or molecular abnormalities that make them different from normal cells, and these differences can be targeted with specific drugs or therapies.

In healthcare, molecular targeted therapy has revolutionized the treatment of cancer and other diseases. Unlike traditional chemotherapy, which can affect both cancerous and healthy cells, molecular targeted therapies are designed to target only the specific cells or molecules that are involved in the disease process. This can lead to fewer side effects and more effective treatments.

There are several types of molecular targeted therapies, including:

Small molecule inhibitors: These drugs are designed to block the activity of specific molecules involved in the growth and spread of cancer cells.

Monoclonal antibodies: These are antibodies that are designed to bind to specific proteins on the surface of cancer cells and trigger an immune response to destroy them.

Kinase inhibitors: These drugs target specific enzymes called kinases, which are involved in the growth and spread of cancer cells.

Immunotherapies: These treatments are designed to stimulate the body’s immune system to attack cancer cells.

Molecular targeted therapy is used to treat a wide range of cancers, including breast cancer, lung cancer, colon cancer, and leukemia. It is also being studied for use in the treatment of other diseases, such as rheumatoid arthritis and multiple sclerosis.

Overall, molecular targeted therapy has transformed the way we approach cancer treatment and holds great promise for the future of healthcare.

Know anyone building innovative solutions that belong in this  'Molecular Targeted Therapy'?

Topic Community Insights

Total: 5 Product: 0 Solution: 0 Service: 0 News: 0 Events: 5

Related Topic Community


    Medical Subject Headings (MeSH): Molecular Targeted Therapy Topic Insights

    info

    Are there any products that should be added for evaluation? Click here to add/suggest.

    • May
      16

      2nd Next Generation RNA Therapeutics Summit

       May 16 to May 18, 2023 

      Hilton Boston Logan Airport, One Hotel Drive, Boston, Massachusetts, 02128, United States

      2nd Next Generation RNA Therapeutics Summit
    • May
      02

      4th Annual Gene Therapy Analytical Development Europe

       May 2 to May 4, 2023 

      The Tower Hotel, St Katharine's Way, London, England, E1W 1LD, United Kingdom

      4th Annual Gene Therapy Analytical Development Europe
    • April
      23

      49th Annual Meeting of the EBMT

       April 23 to April 26, 2023 

      Le Palais des Congrès de Paris, 2 Place de la Porte Maillot, Paris, Île-de-France, 75017, France

      49th Annual Meeting of the EBMT
    • February
      22

      2nd Next Generation Kinase Inhibitors Summit

       February 22 to February 23, 2023 

      Boston Park Plaza, 50 Park Plaza, Boston, Massachusetts, 02116, United States

      2nd Next Generation Kinase Inhibitors Summit
    • January
      30

      3rd Annual TGF-β for Immuno-Oncology Drug Development Summit

       January 30 to February 1, 2023 

      Marines' Memorial Club & Hotel, 609 Sutter Street, San Francisco, California, 94102, United States

      3rd Annual TGF-β for Immuno-Oncology Drug Development Summit

    Medigy Innovation Network

    Connecting innovation decision makers to authoritative information, institutions, people and insights.

    Medigy Logo

    The latest News, Insights & Events

    Medigy accurately delivers healthcare and technology information, news and insight from around the world.

    The best products, services & solutions

    Medigy surfaces the world's best crowdsourced health tech offerings with social interactions and peer reviews.


    © 2024 Netspective Media LLC. All Rights Reserved.

    Built on Apr 19, 2024 at 8:35am